Trial Profile

A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms VALDAC study

Most Recent Events

13 Dec 2022 Results (n=48) assessing the efficacy of low dose ara-C (LDAC) plus venetoclax in patients with acute myeloid leukemia and measurable residual disease relapse, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
05 Dec 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com